acute pain News
-
Medovate Industry Partner for Esra Residents & Trainees Workshop Event in Portugal
Medovate is delighted to be sponsoring the European Society for the 4th ESRA Residents & Trainees Workshop event, taking place at the Hospital das Forças Armadas on the 1st and 2nd April in Porto, Portugal. As well as being an Industry Partner, Medovate will also be showcasing the SAFIRA® system (SAFer Injection for Regional Anaesthesia) – a pioneering device which is ...
By Medovate
-
Bexson Biomedical Hires Veteran Medical Device Development Leader, Will Focus On New Dosing & Delivery Solutions For Controlled Substances
Bexson Biomedical, Inc., a research-stage company developing dosing and delivery solutions for mental health and pain management indications, announced today the addition of medical device and combination product developer, Sheldon Moberg, to its senior leadership team. As Senior VP, Drug Delivery, Moberg will lead the development of Bexson's drug delivery technologies, starting with a wearable ...
-
DYV-700 Gout Abstract
Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy and Safety Study of a Transdermal Alkalinizing and Pain Relieving Treatment for Acute Gout Pain Objectives: Gout is characterized by a build-up of monosodium urate (MSU) crystals in and around the joints. MSU crystal formation and dissolution is affected by pH. There are reports in the literature of the use of alkalization agents, ...
-
Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation
Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat. No. 10,973,780, describing pharmaceutical formulations and treatment methods including the company's BB106 ketamine therapy. Bexson believes the new ...
-
electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National Spine and Pain Centers (NSPC) affiliated locations across the United States for patients suffering from pain associated with different forms of ...
-
Medovate Announces Us Distribution Agreement with Mercury Medical® For Safira®
Medovate has announced that it has entered into an agreement with Mercury Medical® for primary distribution of the FDA-cleared device SAFIRA® (SAFer Injection for Regional Anesthesia) across the whole of the United States (US). The agreement also includes the newly launched SAFIRA® Palm Operator which has been launched in the US market to offer anesthesiologists more versatility and ...
By Medovate
-
Dyve Biosciences wins FDA nod for Phase 2 transdermal drug delivery trial
Dyve Biosciences received FDA clearance to begin a Phase 2 study of its DYV-700 transdermal therapeutic for the treatment of acute gout pain. Thousand Oaks, Calif.-based Dyve said it plans to begin the Targets study in the first quarter of 2020. It is slated to be a double-blind, placebo-controlled, randomized clinical trial to evaluate the efficacy of DYV-700 in patients with acute gout flare. ...
-
Intecore Physical Therapy the First and ONLY PT Clinic in the Western US to Integrate KneeKG into Clinics
Outpatient orthopedic and sports medicine rehabilitation provider, Intecore Physical Therapy, broadens its care and support for patients experiencing knee pain with the addition of the KneeKG™ System into all of their clinics. Developed by Emovi, the KneeKG™ is used on the knee, like an EKG is for the heart, by providing valuable data that enables the Physical Therapy team to ...
By Emovi
-
Dyve Biosciences Receives FDA Clearance to Begin Phase 2 Study of DYV-700 for Treatment of Acute Gout Pain
THOUSAND OAKS, Ca.--(BUSINESS WIRE)--Dyve Biosciences, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with a Phase 2 trial of DYV-700, the company’s topically administered therapeutic being developed to reduce the pain and duration of an acute gout flare. Dyve intends to initiate the Phase 2 trial, the TARGETS Study (NCT04130204), ...
-
Stevanato Group S.p.A. and Bexson Biomedical, Inc. Expand Collaboration to Treat a Range of Mental Health Conditions With an On-body Device
Italian-based Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Bexson Biomedical, Inc., a research stage company developing subcutaneous therapies for pain management and mental health disorders, announced today that they have signed an agreement expanding their ...
-
Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage ...
-
Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
-
Murphy Highlights Norwalk’s Biowave as “Innovator of the Month”
U.S. Senator Chris Murphy (D-Conn.) announced that BioWave, based in Norwalk, CT, has been named April’s “Innovator of the Month.” BioWave is a patented smarter pain blocking technology that provides immediate, deep, long lasting relief of severe pain. BioWave devices deliver therapeutic electrical signals through skin directly to pain nerves in deep tissue to prevent pain ...
-
Cara Therapeutics Announces Difelikefalin (KORSUVA) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd., and its sublicensee Kissei Pharmaceutical Co., Ltd., confirmed the primary endpoint was achieved in a Japanese Phase 3 clinical study ...
-
Dyve Biosciences Announces Research and Development Collaboration with Moffitt Cancer Center
CAMARILLO, Calif. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced a joint, two-year research collaboration with Moffitt Cancer Center. The collaboration will study Dyve’s systemic buffering agent, ...
-
FYZICAL Therapy and Balance Centers El Paso Brings New Technology to its Clinics to Support Patients Faced With Knee Pain
FYZICAL Therapy and Balance Centers – El Paso, announces today the launch of KneeKGTM into all four of their locations. Developed by Emovi, the KneeKG is for the knee, like an EKG is for the heart and provides valuable data that enables physicians and other healthcare professionals to determine the most appropriate patient-specific care plan to restore optimal knee function. Knee pain is ...
By Emovi
-
HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) that was established in January 2019. Leveraging its proprietary REVEAL-TxTM disease modeling platform, HemoShear has earned two milestone payments to date in accordance with the ...
-
gammaCore Sapphire Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium. CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout ...
-
Dyve Biosciences Hosting Key Opinion Leader Webinar on Gout and DYV702
THOUSAND OAKS, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that it will host a key opinion leader (KOL) webinar on gout on Tuesday, November 23, 2021 at 11:00am Eastern Time. A live Q&A session will follow the formal presentations. To register for the event, please click HERE. The webinar will ...
-
electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within selected managed care health systems. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you